| For: | Wan JY, Zhang D, Wu XH, Yang H, Dong C. Progress of immune checkpoint inhibitors in gastric cancer. World J Gastrointest Oncol 2025; 17(8): 109613 [PMID: 40837753 DOI: 10.4251/wjgo.v17.i8.109613] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i8/109613.htm |
| Number | Citing Articles |
| 1 |
Xu Lu, Jing Li, Ming-Liang Wang, Hui-Zhen Wang, Yong-Xiang Li. PARVA promotes gastric cancer progression through FBXO15-related PI3K/AKT signaling. World Journal of Gastrointestinal Oncology 2026; 18(10): 121827 doi: 10.4251/wjgo.121827
Abstract(19) |
Core Tip(16) |
Full Article(HTML)(3)
|
Full Article (PDF)-42411K(1)
|
Full Article with Cover (PDF)-42668K(1)
|
Full Article (XML)-83K(3)
|
Audio-933K(0)
|
Peer-Review Report-259K(5)
|
Answering Reviewers-241K(4)
|
Supplementary Material-152K(3)
|
Times Cited (0)
|
Total Visits (10)
|
Open
|
| 2 |
Rui Guo, Meng Gao. Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors. World Journal of Gastroenterology 2026; 32(34): 119567 doi: 10.3748/wjg.v32.i34.119567
|
| 3 |
Zhouwei Zhan, Ruyu Lin, Yigui Chen, Sha Huang, Luping Lin, Hanchen Zheng, Xiaojie Wang, Xiaoyan Lin, Zengqing Guo, Qiaoting Hu, Bijuan Chen. Plasma immune proteome-based risk score predicts survival in advanced gastric cancer treated with PD-1 inhibitors and chemotherapy. Frontiers in Immunology 2026; 16 doi: 10.3389/fimmu.2025.1715993
|